Targeting CD19 with genetically modified EBV-specific human T lymphocytes

C. Roessig, S. P. Scherer, A. Baer, J. Vormoor, C. M. Rooney, Malcolm Brenner, H. Juergens

Research output: Contribution to journalArticlepeer-review

25 Scopus citations

Abstract

Human Epstein-Barr virus-specific T cells were genetically modified to express chimeric receptors specific for human CD19, which is expressed on the cell surface of most B cell malignancies. The receptor-modified EBV-specific T cells can be expanded and maintained long term in the presence of EBV-infected B cells. They recognize autologous EBV-infected targets through their conventional T cell receptor, and allogeneic EBV-infected targets and tumor targets through their chimeric receptor. They efficiently lyse both EBV and CD19-positive tumor targets in the absence of background cytotoxicity against CD19-negative targets. Donor-derived EBV-specific T cells expressing chimeric anti-tumor receptors may represent a source of effector cells that could be safely administered to leukemia patients to eradicate minimal residual disease after allogeneic bone marrow transplantation.

Original languageEnglish (US)
Pages (from-to)S42-S43
JournalAnnals of Hematology
Volume81
Issue numberSUPPL. 2
StatePublished - 2002

ASJC Scopus subject areas

  • Hematology

Fingerprint

Dive into the research topics of 'Targeting CD19 with genetically modified EBV-specific human T lymphocytes'. Together they form a unique fingerprint.

Cite this